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Background
Cytokine-induced killer (CIK) cells have been exten-
sively used in treatment of cancer patients in China.
Clinical trials demonstrated that there were markedly
decreased tumor nodules in size in a patient with
advanced pancreatic adenocarcinoma following four
cycles of CIK cell infusion and thus the patient had a
longer progression-free survival. Moreover, immu-
notherapy with CIK cells in combination with che-
motherapy had more potential benefits including longer
progression-free survival and overall survival in patients
with cancer such as advanced gastric cancer and non-
small-cell lung cancer as compared with chemotherapy
alone. In addition, dendritic cell (DC)-CIK cells have
increased proliferation ability, cytokine secretion and
anti-tumor activity as compared with CIK cells alone.
Results
A clinical trial showed that immunotherapy with tumor
lysate-pulsed DC-CIK cells could significantly increase
overall survival rates than no treatment control in renal
cancer carcinoma patients. Thus, nowadays, DC-CIK
cells have also been extensively used in treatment of
cancer patients in China although the efficacy and
mechanisms of adoptive cell transfer therapy with DC-
CIK cells remains to be determined. In one word, the
accumulation of basic researches and clinical studies
related to cancer immunotherapy with CIK and DC-CIK
cells has confirmed their safety and feasibility in treating
malignant diseases. However, at present, there are still no
uniform criteria or large-scale preparations of CIK and
DC-CIK cells and the overall clinical response is difficult
to evaluate due to lack of practical and appropriate
criteria.
Conclusions
Large-scale, controlled, grouped, and multi-center clinical
trials on CIK and DC-CIK cell-based immunotherapy
should be conducted in the near future.
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